TA-CD
TA-CD
TA-CD (/tɑː-siː-diː/) is an experimental vaccine developed for the treatment of cocaine addiction. It is designed to stimulate the immune system to attack the cocaine molecules, preventing them from reaching the brain and thereby nullifying their psychoactive effects.
Etymology
The name "TA-CD" is derived from the initials of the two companies that initially developed the vaccine: Therapeutic Antibodies and Cantab Discovery.
Mechanism of Action
TA-CD works by stimulating the immune system to produce antibodies that bind to cocaine molecules in the bloodstream. This binding prevents the cocaine from crossing the blood-brain barrier, thus preventing the drug's psychoactive effects.
Clinical Trials
Several clinical trials have been conducted to test the efficacy and safety of TA-CD. These trials have shown promising results, with participants showing reduced cocaine use and fewer cravings. However, further research is needed to confirm these findings and to determine the optimal dosage and administration schedule.
Related Terms
External links
- Medical encyclopedia article on TA-CD
- Wikipedia's article - TA-CD
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski